Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Varenicline Among HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected patients~* adults~* regular smokers (at least 10 cigarettes a day during the last year)~* motivated to stop smoking~* followed in one of the participating clinical ward,~* signed written inform consent~Exclusion Criteria:~* current co-dependency to another psychoactive substance~* ongoing depressive episode~* history of suicidal attempt~* ongoing treatment by interferon~* treatment by efavirenz for less than three months or not tolerated~* previous use of varenicline~* ongoing treatment by bupropion-SR or nicotinic substitute~* ongoing pregnancy~* ongoing breastfeeding~* hypersensitivity to varenicline or to one of its excipients~* drivers, air traffic controller

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): placebo titrated to 2 pills twice daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).